Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW 9,020.00
-40.00 (-0.44%)
Last updated: Apr 29, 2026, 1:50 PM KST
Prestige BioPharma Revenue
Prestige BioPharma had revenue of 7.70B KRW in the quarter ending December 31, 2025, with 147.35% growth. This brings the company's revenue in the last twelve months to 19.02B, up 224.15% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.
Revenue (ttm)
19.02B
Revenue Growth
+224.15%
P/S Ratio
5.71
Revenue / Employee
n/a
Employees
n/a
Market Cap
108.65B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Oncocross | 370.46M |
| IMB Dx | 5.33B |
| iNtRON Biotechnology | 5.74B |
| CG Invites | 27.39B |
| Amicogen | 41.98B |
| GeneOne Life Science | 23.04B |
| ENCell | 5.26B |
| Vaxcell-Bio Therapeutics | 1.90B |